Skip to main content
. 2021 Oct 23;118(11):2478–2487. doi: 10.1093/cvr/cvab331

Figure 3.

Figure 3

Results of pathway overrepresentation analyses of patients with atrial fibrillation vs. sinus rhythm in the index cohort (A, n = 1620) and the validation cohort (B, n = 1219) of BIOSTAT-CHF. The nodes in blue represent the 24 biomarkers that were significantly up-regulated in patients with atrial fibrillation when compared with those in sinus rhythm in the index cohort (A), and eight biomarkers that were significantly up-regulated in these patients in the validation cohort (B). The nodes in red reveal the overrepresented pathways of these biomarkers. Based on current knowledge, the blue nodes below the figures are biomarkers that were not found to be overrepresented in a specific biological pathway. CHI3L1, chitinase 3 like 1; CPA1, carboxypeptidase A1; CPB1, carboxypeptidase B1; CSTB, cystatin B; FABP4, fatty acid-binding protein 4, adipocyte; GDF-15, growth differentiation factor 15; HSPG2, heparan sulphate proteoglycan 2; IGFBP-1, insulin like growth factor binding protein 1; IGFBP-2, insulin-like growth factor-binding protein 2; IGFBP-7, insulin like growth factor binding protein 7; IL1RL-1, interleukin 1 receptor like 1; MB, myoglobin; MMP-2, matrix metallopeptidase 2; MMP-3, matrix metallopeptidase 3; NOTCH3, neurogenic locus notch homolog protein 3; NPPB, natriuretic peptide B; PLAT, plasminogen activator, tissue type; PLAUR, plasminogen activator, urokinase receptor; SPON-1, spondin-1; SPP-1, secreted phosphoprotein 1; TFF3, trefoil factor 3; TIMP-4, metalloproteinase inhibitor 4; TNFRSF1A, TNF receptor superfamily member 1A; TNFRSF1B, TNF receptor superfamily member 1B.